Oct 16, 2025 08:47AM Citius Oncology partners with EVERSANA for LYMPHIR drug launch

Aug 22, 2025 08:47AM Citius Oncology deploys AI platform ahead of LYMPHIR launch

Jul 15, 2025 08:32AM Citius Oncology signs distribution deal with Cencora for LYMPHIR

Jul 8, 2025 08:34AM Citius Pharmaceuticals regains Nasdaq compliance

Jun 17, 2025 08:10AM Citius Oncology (CTOR) Anticipates Commercial Launch of LYMPHIR in 2025

Jun 10, 2025 07:01AM Citius Pharmaceuticals (CTXR) Prices $15.8M Offering at $1.22/sh

Jun 9, 2025 08:57AM Citius Oncology (CTOR) stock soars on distribution deal

Jun 9, 2025 08:38AM Citius (CTOR) enters distribution agreement with Cardinal Health (CAH)

May 14, 2025 06:16PM Citius Pharmaceuticals (CTXR) Misses Q2 EPS by 11c

Apr 14, 2025 06:44AM Citius Pharmaceuticals (CTXR) PT Lowered to $4 at H.C. Wainwright

Apr 1, 2025 09:01AM Citius Pharmaceuticals (CTXR) Announces 1.74M Share Offering at $1.15/sh

Feb 6, 2025 08:57AM Citius Pharmaceuticals (CTXR) and Citius Oncology (CTOR) Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

Jan 8, 2025 08:00AM Citius Pharmaceuticals (CTXR) Prices 743K Share Offering at $4.035/sh

Jan 7, 2025 08:08AM Citius Pharmaceuticals (CTXR) and Citius Oncology (CTOR) Highlight LYMPHIR Commercial Launch Planned for H1 of 2025

Dec 30, 2024 07:02AM D. Boral Capital Upgrades Citius Pharmaceuticals (CTXR) to Buy

Nov 25, 2024 08:04AM Citius Pharmaceuticals (CTXR) Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok Program and Pathway to Approval

Nov 22, 2024 09:00AM Citius Pharmaceuticals (CTXR) Announces 1-for-25 Reverse Stock Split

Nov 15, 2024 01:30PM Citius Pharmaceuticals (CTXR) Prices 12M Share Offering at $0.25/sh

Nov 11, 2024 08:45AM Citius Pharmaceuticals (CTXR) and Citius Oncology (CTOR) Report Prelim Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab and LYMPHIR

Aug 13, 2024 07:01AM Citius Pharmaceuticals, Inc. (CTXR) Misses Q3 EPS by 1c

Aug 8, 2024 07:00AM Citius Pharmaceuticals (CTXR) Receives FDA Approval for LYMPHIR (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Aug 5, 2024 08:02AM Citius Pharmaceuticals (CTXR) Announces TenX Keane Shareholder Approval of Merger with Citius Oncology

Jul 18, 2024 07:00AM Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)

Jul 17, 2024 08:00AM Analysts Hunt for Undervalued Biotech Stocks

Jul 15, 2024 09:35AM EF Hutton Starts Citius Pharmaceuticals (CTXR) at Buy

Jul 11, 2024 11:00AM Bloodstream Infections - From Threats to Solutions

Jul 11, 2024 08:00AM Biopharma Stocks Transformative Innovation for the Future of Health

Jul 10, 2024 09:10AM Citius Pharmaceuticals (CTXR) Details Near-Term Milestones for Late-Stage Candidates